China's Contract Manufacturing Growth Tied To Losses In The West
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's contract manufacturing market, the world's largest supplier of bulk drug materials, is expected to reach a value of roughly $2 billion in FY2010, according to consulting firm Frost & Sullivan
You may also be interested in...
China's State FDA Imposes New Regulatory Requirements On CMOs And Third-party Contracts
SHANGHAI - In a bid to prevent the export of counterfeit medicines, China is tightening its supervision of contract manufacturing organizations doing work for overseas drug makers. To that end, China's State FDA recently issued a notice on new rules governing cross-border contract manufacturing
China's State FDA Imposes New Regulatory Requirements On CMOs And Third-party Contracts
SHANGHAI - In a bid to prevent the export of counterfeit medicines, China is tightening its supervision of contract manufacturing organizations doing work for overseas drug makers. To that end, China's State FDA recently issued a notice on new rules governing cross-border contract manufacturing
Shifting Supply Chain To Asia Will Require More Quality Control Vigilance - World Pharma Manufacturing Summit
SHANGHAI - As Big Pharma continues to shift API manufacturing and contract manufacturing to Asia, it must be vigilant in verifying quality even as regulatory agencies in the region enact more stringent guidelines, according to speakers at the World Pharma Manufacturing Summit in Shanghai